SecBot SecBot

CVKD

Cadrenal Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001937993 Biotech & Drug Discovery
$0.9295 −0.03 (−3.18%)
Oct 26 4:00 PM ET · prev $0.9600
Market cap
$3.5M
Nano cap
Median target
$13.00
+1299% · range $12.00–17.00
Next earnings
Nov 9
in 14 days · EPS est. −$0.94
1 year
−92.9%
from $13.10 · Oct 27
30 days
−17.0%
from $1.12
52-week range
$0.8720–13.66
−93% from high · low Oct 12
Avg volume 20D
203.3K
Oct 7 spike 1.78M
Short interest
105.9K
≈3.0% of shares · −10.8%
Days to cover
1.1
at average volume
Insider net
-$388.3K
0 buyers · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 2 bullish oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 9, 2026
Strongest BULLISH Cadrenal Therapeutics announced a formal strategic process to maximize shareholder value, engaging Tungsten…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $388.3K.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 0 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$1.445 → −$0.935 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −10.8% to 105.9K shares. 1.1 days to cover, ≈3.0% of shares.

  • TrendDOWNTREND

    22% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED1,112$3.7K
MORGAN STANLEYDOUBLED706$2.4K
GEODE CAPITAL MANAGEMENT, LLCADD21,626$110.7K
BlackRock, Inc.ADD5,496$28.1K
OSAIC HOLDINGS, INC.TRIM300$1.5K
Rockefeller Capital Management L.P.TRIM150$768.00
MORGAN STANLEYNEAR_EXIT100$512.00
UBS Group AGNEAR_EXIT3$15.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Apr 2026
12-month targets · 3 analysts

Price is below the lowest target. Median implies +1299%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Apr 7, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
May 16, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Nov 11, 2024HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jun 6, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
May 9, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Mar 14, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$388.3K
sold · 1 insider
DateInsiderTypeValue
Oct 9, 2026
Cole Jeffrey Scott
Chief Operating Officer
AWARD150,000 sh
Oct 9, 2026
WILSON GLYNN
Director
AWARD75,000 sh
Oct 9, 2026
MURPHY JOHN RAYMOND
Director
AWARD75,000 sh
Oct 9, 2026
Pham Quang X
Chairman and CEO
AWARD200,000 sh
Oct 9, 2026
Golden Lee Scott
Director
AWARD75,000 sh
Jun 29, 2026
Pham Quang X
Chairman and CEO
SELL$22.4K
Jun 26, 2026
Pham Quang X
Chairman, CEO and Interim CFO
SELL$27.5K
Jun 25, 2026
Pham Quang X
Chairman, CEO and Interim CFO
SELL$6.4K

Earnings setup

Estimates
Nov 9
reports in 14 days
−$0.94
EPS estimate, this quarter
+35%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.94-$0.94–-$0.93-43.8%$0.00
Next Q-$0.88-$0.89–-$0.87-17.3%$0.00
Current FY-$3.92-$3.92–-$3.91-22.7%$0.00
Next FY-$3.40-$3.55–-$3.26-10.2%$0.00

Short side

FINRA· Sep 30, 2026
105,945
shares short
-10.8%
vs prior settlement
1.1
days to cover
≈3.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 9, 2026 Insider
Cole Jeffrey Scott was granted 150,000 shares
Chief Operating Officer
Oct 9, 2026 Insider
WILSON GLYNN was granted 75,000 shares
Director
Oct 9, 2026 Insider
MURPHY JOHN RAYMOND was granted 75,000 shares
Director
Oct 7, 2026 SEC
Cadrenal Therapeutics announced a formal strategic process to maximize shareholder value, engaging Tungsten Advisors…
8-K — Impact 6/10
Sep 21, 2026 Routine
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
PONTE VEDRA, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a
Aug 31, 2026 SEC
Cadrenal Therapeutics announced positive feedback from an FDA Type D meeting for its Phase 3 registrational study of…
8-K — Impact 6/10
Jul 21, 2026 SEC
Cadrenal Therapeutics' S-3 shelf registration statement (File No. 333-297432) became effective on July 20, 2026…
EFFECT — Impact 2/10
Jul 1, 2026 Press
Cadrenal Therapeutics announced a $3M private placement with H.C. Wainwright, selling 960,000 shares and warrants that…
Impact 5/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
CVKD Q3 2026 Earnings Scheduled — 2026-11-09
Recent
Sep 21, 2026
Company news
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
PONTE VEDRA, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing…
Aug 31, 2026
FDA
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study
Aug 10, 2026
Earnings date
CVKD Q2 2026 Earnings Scheduled — 2026-08-10
Jul 1, 2026
Offering
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon the exercise in full of warrants
Jun 18, 2026
Press release
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to global pharmaceutical partners at the 2026 BIO…

SecBot reports

12 filings · 3 press releases · 4 bullish · 2 bearish · 1 mixed · 5 neutral
All CVKD filing & press-release reports (15)